Cellular Senescence as the Key Intermediate in Tau-Mediated Neurodegeneration
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Neuroinflammation is thought to play a key role in the progression of neurodegenerative disease such as Alzheimer's disease (AD). Given the apparent nexus of inflammatory disease with the secretory-associated senescence phenotype (SASP) of cellular senescence, two reports found that tau-mediated neurodegeneration involves induction of senescence in astrocytes, microglia, and possibly even neurons. Elimination of senescent cells by pharmacologically induced genetic ablation or by senolytic drugs blocks progression of mutant human tau-mediated neurodegeneration in mice. This work suggests a working hypothesis through which tau activation leads to senescence and then tau propagation throughout the brain is supported by, and neurotoxicity is caused by, SASP, forming a pathological positive feedback loop. Although preliminary, these data suggest that the development of senolytics for AD and other tauopathies, especially early disease, and possibly senomodulatory drugs for later stage neurodegenerative disease may prove fruitful.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Senolytics improve physical function and increase lifespan in old age
Xu, M., Pirtskhalava, T., Farr, J. N., Weigand, B. M., Palmer, A. K., Weivoda, M. M., Inman, C. L., Ogrodnik, M. B., Hachfeld, C. M., Fraser, D. G., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0092-9 · Cited by 2,287
Tau Suppression in a Neurodegenerative Mouse Model Improves Memory Function
SantaCruz, K., Lewis, J., Spires, T., Paulson, J., Kotilinek, L., Ingelsson, M., Guimaraes, A., DeTure, M., Ramsden, M., McGowan, E., et al. (2005) · Science · doi:10.1126/science.1113694 · Cited by 2,014
Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model
Roberson, E. D., Scearce-Levie, K., Palop, J. J., Yan, F., Cheng, I. H., Wu, T., Gerstein, H., Yu, G.-Q., & Mucke, L. (2007) · Science · doi:10.1126/science.1141736 · Cited by 1,892 · cited 1×
“On the contrary, reducing endogenous tau ameliorates A b -induced deficits in a mouse model of AD that does not carry any tau mutation, 6 supporting the contribution of tau to the pathology of AD.”
Depletion of microglia and inhibition of exosome synthesis halt tau propagation
Asai, H., Ikezu, S., Tsunoda, S., Medalla, M., Luebke, J., Haydar, T., Wolozin, B., Butovsky, O., Kügler, S., & Ikezu, T. (2015) · Nature Neuroscience · doi:10.1038/nn.4132 · Cited by 1,591 · cited 1×
“17 Inflammatory processes are known to play an important role in the progression of neurodegenerative diseases such as AD.”
Clearance of senescent glial cells prevents tau-dependent pathology and cognitive decline
Bussian, T. J., Aziz, A., Meyer, C. F., Swenson, B. L., van Deursen, J. M., & Baker, D. J. (2018) · Nature · doi:10.1038/s41586-018-0543-y · Cited by 1,289 · cited 6×
“21 These results illuminate a potential path to potentially preventing and maybe treating tauopathies such as AD with senolytics.”
InfluentialCellular senescence: a translational perspective
Kirkland, J. L., & Tchkonia, T. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.04.013 · Cited by 1,013 · cited 1×
“29,30 These mice already have NFTs at 20 months.”
Roles of tau protein in health and disease
Guo, T., Noble, W., & Hanger, D. P. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1707-9 · Cited by 1,003
Mitochondria are required for pro-ageing features of the senescent phenotype
Correia‐Melo, C., Marques, F. D., Anderson, R., Hewitt, G., Hewitt, R., Cole, J., Carroll, B. M., Miwa, S., Birch, J., Merz, A., et al. (2016) · The EMBO Journal · doi:10.15252/embj.201592862 · Cited by 796
Tau and Aβ imaging, CSF measures, and cognition in Alzheimer’s disease
Brier, M. R., Gordon, B., Friedrichsen, K., McCarthy, J., Stern, A., Christensen, J., Owen, C., Aldea, P., Su, Y., Hassenstab, J., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf2362 · Cited by 734
Jurk, D., Wang, C., Miwa, S., Maddick, M., Korolchuk, V., Tsolou, A., Gonos, E. S., Thrasivoulou, C., Jill Saffrey, M., Cameron, K., et al. (2012) · Aging Cell · doi:10.1111/j.1474-9726.2012.00870.x · Cited by 598
Tau protein aggregation is associated with cellular senescence in the brain
Musi, N., Valentine, J. M., Sickora, K. R., Baeuerle, E., Thompson, C. S., Shen, Q., & Orr, M. E. (2018) · Aging Cell · doi:10.1111/acel.12840 · Cited by 595 · cited 14×
“At 15 months, when the 3xTgAD mice show extensive amyloid deposits and hyperphosphorylated tau, but no NFTs, there was no increase in p16ink4a suggesting that few senescent cells were present, again showing a correlation with NFTs. 22 However, there are caveats.”
InfluentialInhibition of neuronal maturation in primary hippocampal neurons from tau deficient mice
Dawson, H. N., Ferreira, A., Eyster, M. V., Ghoshal, N., Binder, L. I., & Vitek, M. P. (2001) · Journal of Cell Science · doi:10.1242/jcs.114.6.1179 · Cited by 527
Tau Protein Disrupts Nucleocytoplasmic Transport in Alzheimer’s Disease
Eftekharzadeh, B., Daigle, J. G., Kapinos, L. E., Coyne, A., Schiantarelli, J., Carlomagno, Y., Cook, C., Miller, S. J., Dujardin, S., Amaral, A. S., et al. (2018) · Neuron · doi:10.1016/j.neuron.2018.07.039 · Cited by 460
Ageing, Cellular Senescence and Neurodegenerative Disease
Kritsilis, M., V. Rizou, S., Koutsoudaki, P. N., Evangelou, K., Gorgoulis, V. G., & Papadopoulos, D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19102937 · Cited by 448 · cited 2×
“18 Senescence can be defined as a set of overlapping, inter-acting cell states characterized by irreversible cell cycle withdrawal, SASP, DNA damage, senescence-associated beta galactosidase (SA-B-Gal), expression of cell cycle inhibitory proteins, especially p16ink4a, senescence-associated…”
Mutations causing neurodegenerative tauopathies
Goedert, M., & Jakes, R. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2004.08.007 · Cited by 438
Spires, T. L., Orne, J. D., SantaCruz, K., Pitstick, R., Carlson, G. A., Ashe, K. H., & Hyman, B. T. (2006) · The American Journal of Pathology · doi:10.2353/ajpath.2006.050840 · Cited by 401
Tau and neuroinflammation: what impact for Alzheimer's disease and tauopathies?
Laurent, C., Buée, L., & Blum, D. (2018) · Biomedical Journal · doi:10.1016/j.bj.2018.01.003 · Cited by 348 · cited 11×
“At 15 months, when the 3xTgAD mice show extensive amyloid deposits and hyperphosphorylated tau, but no NFTs, there was no increase in p16ink4a suggesting that few senescent cells were present, again showing a correlation with NFTs. 22 However, there are caveats.”
InfluentialViolet, M., Delattre, L., Tardivel, M., Sultan, A., Chauderlier, A., Caillierez, R., Talahari, S., Nesslany, F., Lefebvre, B., Bonnefoy, E., et al. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00084 · Cited by 251
The Association of Tau With Mitochondrial Dysfunction in Alzheimer’s Disease
Cheng, Y., & Bai, F. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00163 · Cited by 239 · cited 1×
“22 Expression of pathological human tau mutants in mice was already known to negatively impact mitochondrial function, 25 in part, by altering mitochondrial fusion, so establishing a connection between senescence and tau-mediated neuropathology is potentially important.”
Mansuroglu, Z., Benhelli-Mokrani, H., Marcato, V., Sultan, A., Violet, M., Chauderlier, A., Delattre, L., Loyens, A., Talahari, S., Bégard, S., et al. (2016) · Scientific Reports · doi:10.1038/srep33047 · Cited by 146 · cited 2×
“These hybrid P301L/Mapt(null) mice develop a lower density of NFTs and significantly reduced neurodegeneration (Weg-mann et al. 16 ).”
Removing endogenous tau does not prevent tau propagation yet reduces its neurotoxicity
Wegmann, S., Maury, E. A., Kirk, M. J., Saqran, L., Roe, A., DeVos, S. L., Nicholls, S., Fan, Z., Takeda, S., Cagsal‐Getkin, O., et al. (2015) · The EMBO Journal · doi:10.15252/embj.201592748 · Cited by 132
Tracking progressive pathological and functional decline in the rTg4510 mouse model of tauopathy
Blackmore, T., Meftah, S., Murray, T. K., Craig, P. J., Blockeel, A., Phillips, K., Eastwood, B., O’Neill, M. J., Marston, H., Ahmed, Z., et al. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0306-2 · Cited by 66 · cited 1×
“27,28 It would have been useful to treat mice with doxycycline to freeze the extent of hyperphosphorylated tau and NFTs at various stages and determine if senescence markers such as p16ink4a remained correlated.”
Research works printed but not linked: 11
- 10.1002/ana.410400204 · DOI · Paper page
- 10.14348/molcells.2017.0096 · DOI · Paper page
- 10.1016/j.trci.2017.04.005 · DOI · Paper page
- 10.1021/acschemneuro.7b00188 · DOI · Paper page
- 10.1016/j.neuroscience.2016.03.044 · DOI · Paper page
- 10.1038/s41598-018-21596-3 · DOI · Paper page
- 10.1007/s00018-018-2879-8 · DOI
- 10.1387/ijdb.180081my · DOI · Paper page
- 10.18632/oncotarget.12752 · DOI · Paper page
- 10.1128/JVI.00865-07 · DOI · Paper page
- 10.1007/s00401-016-1644-z · DOI · Paper page
Cited by
Cellular Senescence in Neurodegenerative Diseases
Martínez-Cué, C., & Rueda, N. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00016 · Cited by 281
Aging, Cellular Senescence, and Alzheimer’s Disease
Liu, R.-M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23041989 · Cited by 267
Astrocyte Senescence and Alzheimer’s Disease: A Review
Han, X., Zhang, T., Liu, H., Mi, Y., & Gou, X. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00148 · Cited by 177
Senescence in Post-Mitotic Cells: A Driver of Aging?
von Zglinicki, T., Wan, T., & Miwa, S. (2021) · Antioxidants & Redox Signaling · doi:10.1089/ars.2020.8048 · Cited by 170
“This, on one hand, promotes tissue remodeling and repairing (33, 75, 95, 96, 125), but on the other hand, it may contribute to tissue functional decline, age-related tissue degeneration, and tumorigenesis (22, 31, 56, 67, 87).”
BackgroundViel, T., Toricelli, M., Pereira, A. R., Souza Abrao, G., Malerba, H., Maia, J., & Buck, H. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.286952 · Cited by 102
“The phosphorylation of tau protein, for instance, has been linked to the release of SASPs and promotion of toxicity in central nervous system cells (Mendelsohn and Larrick, 2018).”
Metadata
- Authors
- Mendelsohn, A. R., & Larrick, J. W.
- Venue
- Rejuvenation Research
- Publisher
- SAGE Publications
- Published
- 2018-12
- Volume
- 21
- Issue
- 6
- Pages
- 572-579
- ISSN
- 1094-5458 (ISSN-L)
- 1549-1684
- 1557-8577
- OpenAlex
- W2902472741
- Cited by
- 37
- References
- 22
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.